CONMED (NYSE:CNMD) Price Target Raised to $50.00

CONMED (NYSE:CNMD) had its price objective increased by JPMorgan Chase & Co. from $45.00 to $50.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Zacks Research upgraded CONMED from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded CONMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 21st. Piper Sandler reaffirmed a “neutral” rating and set a $45.00 price objective (up from $39.00) on shares of CONMED in a research report on Thursday, July 30th. Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Finally, Wells Fargo & Company boosted their target price on shares of CONMED from $46.00 to $49.00 and gave the company an “equal weight” rating in a research report on Thursday. Seven investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $44.00.

CONMED Stock Down 3.3%

Shares of CNMD opened at $44.21 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.69 and a current ratio of 1.49. CONMED has a 52 week low of $31.44 and a 52 week high of $53.66. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of 18.27, a PEG ratio of 2.00 and a beta of 0.94. The stock has a fifty day moving average of $47.06 and a 200-day moving average of $41.45.

CONMED (NYSE:CNMD) last announced its quarterly earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.04. The firm had revenue of $335.56 million during the quarter, compared to analysts’ expectations of $336.28 million. CONMED had a net margin of 5.36% and a return on equity of 13.93%. The company’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the company posted $1.08 EPS. As a group, sell-side analysts anticipate that CONMED will post 4.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CONMED

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNMD. Signaturefd LLC raised its holdings in shares of CONMED by 82.7% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock worth $25,000 after purchasing an additional 248 shares during the period. Rockefeller Capital Management L.P. lifted its stake in CONMED by 48.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,043 shares of the company’s stock valued at $42,000 after purchasing an additional 341 shares during the last quarter. Choreo LLC grew its holdings in CONMED by 3.0% during the third quarter. Choreo LLC now owns 16,571 shares of the company’s stock valued at $766,000 after purchasing an additional 480 shares during the period. HB Wealth Management LLC grew its holdings in CONMED by 4.0% during the first quarter. HB Wealth Management LLC now owns 16,620 shares of the company’s stock valued at $588,000 after purchasing an additional 636 shares during the period. Finally, Moore Capital Management LP increased its position in CONMED by 2.6% in the second quarter. Moore Capital Management LP now owns 25,230 shares of the company’s stock worth $826,000 after buying an additional 651 shares during the last quarter.

Trending Headlines about CONMED

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: CONMED raised its fiscal 2026 EPS outlook to $4.54-$4.61, with the midpoint above the $4.54 analyst consensus. The company maintained revenue guidance of approximately $1.4 billion, in line with expectations. CONMED Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Third-quarter adjusted earnings of $1.04 per share exceeded the $1.00 consensus estimate. JPMorgan raised its price target from $45 to $50, while Wells Fargo increased its target from $46 to $49, suggesting analysts see additional upside. CONMED Q3 Earnings Top Estimates
• Neutral Sentiment: Both JPMorgan and Wells Fargo retained neutral-style ratings—“neutral” and “equal weight”—despite their higher targets. This indicates improved valuation expectations but no strong bullish conviction.
• Negative Sentiment: Quarterly revenue of approximately $335.6 million was essentially in line with estimates but declined about 0.7% year over year. EPS also fell from $1.08 in the prior-year quarter, signaling limited near-term operating momentum. CONMED Q3 Profit Rises and Updates 2026 Guidance

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company’s orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.